These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34650428)

  • 1. Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors.
    Seong JM; Kim JJ; Kim HJ; Sohn HS
    Front Pharmacol; 2021; 12():689885. PubMed ID: 34650428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
    Seong JM; Kim JJ; Kim HJ; Sohn HS
    Cardiovasc Diabetol; 2020 Jun; 19(1):95. PubMed ID: 32571319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
    Huang TL; Hsiao FY; Chiang CK; Shen LJ; Huang CF
    PLoS One; 2019; 14(5):e0215248. PubMed ID: 31112536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease.
    Baksh SN; Segal JB; McAdams-DeMarco M; Kalyani RR; Alexander GC; Ehrhardt S
    PLoS One; 2020; 15(10):e0240141. PubMed ID: 33057387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
    Persson F; Nyström T; Jørgensen ME; Carstensen B; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Eriksson JW; Norhammar A; Bodegard J; Birkeland KI
    Diabetes Obes Metab; 2018 Feb; 20(2):344-351. PubMed ID: 28771923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.
    Sütő G; Molnár GA; Rokszin G; Fábián I; Kiss Z; Szekanecz Z; Poór G; Jermendy G; Kempler P; Wittmann I
    BMJ Open Diabetes Res Care; 2021 Jan; 9(1):. PubMed ID: 33472796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
    Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
    J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study.
    Hou WH; Chang KC; Li CY; Ou HT
    Br J Clin Pharmacol; 2018 Sep; 84(9):2029-2039. PubMed ID: 29766544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
    Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of dipeptidyl peptidase-4 inhibitor use and the risk of asthma development among type 2 diabetes patients.
    Li PF; Chung CH; Liu JS; Lu CH; Su SC; Kuo FC; Ho LJ; Chen KC; Su YT; Chu NF; Lee CH; Hsieh CH; Hung YJ; Lin FH; Chien WC; Liang YJ
    Ther Adv Respir Dis; 2022; 16():17534666221135320. PubMed ID: 36448591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneous Treatment Effects on Cardiovascular Diseases With Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas in Type 2 Diabetes Patients.
    Yang CY; Lin WA; Su PF; Li LJ; Yang CT; Ou HT; Kuo S
    Clin Pharmacol Ther; 2021 Mar; 109(3):772-781. PubMed ID: 32978779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
    Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study.
    Zerovnik S; Kos M; Locatelli I
    BMJ Open; 2021 Sep; 11(9):e051549. PubMed ID: 34518273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of lower extremity amputations in patients with type 2 diabetes using sodium-glucose co-transporter 2 inhibitors.
    Zerovnik S; Kos M; Locatelli I
    Acta Diabetol; 2022 Feb; 59(2):233-241. PubMed ID: 34609620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study.
    Filion KB; Lix LM; Yu OH; Dell'Aniello S; Douros A; Shah BR; St-Jean A; Fisher A; Tremblay E; Bugden SC; Alessi-Severini S; Ronksley PE; Hu N; Dormuth CR; Ernst P; Suissa S;
    BMJ; 2020 Sep; 370():m3342. PubMed ID: 32967856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of dapagliflozin vs DPP-4 inhibitors on a composite endpoint of HbA1c, body weight and blood pressure reduction in the real world.
    Morieri ML; Consoli A; Sesti G; Purrello F; Avogaro A; Fadini GP;
    Diabetes Metab Res Rev; 2021 Jan; 37(1):e3353. PubMed ID: 32453482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: Real world evidence from the Nordic EMPRISE study.
    Nyström T; Toresson Grip E; Gunnarsson J; Casajust P; Karlsdotter K; Skogsberg J; Ustyugova A;
    Diabetes Obes Metab; 2023 Jan; 25(1):261-271. PubMed ID: 36097728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.
    Nyström T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW
    Diabetes Res Clin Pract; 2017 Jan; 123():199-208. PubMed ID: 28056431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective Cohort Analysis of the Reduced Burden of Hypoglycemia Associated with Dipeptidyl Peptidase-4 Inhibitor Use in Patients with Type 2 Diabetes Mellitus.
    Tang Y; Liu J; Hannachi H; Engel SS; Ganz ML; Rajpathak S
    Diabetes Ther; 2018 Dec; 9(6):2259-2270. PubMed ID: 30284688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.